Universite Libre de Bruxelles
Welcome,         Profile    Billing    Logout  
 0 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cnop, Miriam
Meld-ATG, NCT04509791 / 2019-003265-17: MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)

Completed
2
114
Europe
Anti-Human Thymocyte Immunoglobulin, Rabbit, ATG
Universitaire Ziekenhuizen KU Leuven
Diabetes Mellitus, Type 1
12/24
12/24
Ver-A-T1D, NCT04545151 / 2020-000435-45: Verapamil SR in Adults With Type 1 Diabetes

Active, not recruiting
2
138
Europe
Verapamil SR 120 mg, VeraHEXAL KHK 120 mg, Isoptin retard 120 mg, Placebo, Matching Placebo for Verapamil SR 120 mg
Medical University of Graz, Juvenile Diabetes Research Foundation
Diabetes Mellitus, Type 1
05/25
05/26
INNODIA, NCT03936634: An Innovative Approach Towards Understanding and Arresting Type 1 Diabetes

Recruiting
N/A
6000
Europe
University of Cambridge, Innovative Medicines Initiative, Juvenile Diabetes Research Foundation, The Leona M. and Harry B. Helmsley Charitable Trust
Type 1 Diabetes Mellitus
10/22
10/22
REVITA-T2Di, NCT04419779: Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes

Suspended
N/A
320
Europe, US
Duodenal Mucosal Resurfacing (DMR), Duodenal Mucosal Resurfacing (Sham)
Fractyl Health Inc.
Type 2 Diabetes
06/25
01/26
Hamouda, Aïcha
Meld-ATG, NCT04509791 / 2019-003265-17: MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)

Completed
2
114
Europe
Anti-Human Thymocyte Immunoglobulin, Rabbit, ATG
Universitaire Ziekenhuizen KU Leuven
Diabetes Mellitus, Type 1
12/24
12/24

Download Options